Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NRIX
SELLNurix Therapeutics, Inc. · Healthcare · United States · $2.4B · Avg Vol: $47M/d
COMPANY DESCRIPTION
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and inflammatory diseases. The company's competitive moat is centered on its proprietary DELigase discovery platform, which enables the design of small molecules that harness the body's natural ubiquitin-proteasome system. It operates as a leading innovator in the high-potential protein degradation space, backed by strategic collaborations with global pharmaceutical leaders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.6M | 77.0M | 54.5M | 84.0M | 29.5% | 36.8M | 57.7M | 96.4M | 7.1% |
| EPS | -1.69 | -1.24 | -2.88 | -3.05 | — | -3.40 | -2.72 | -2.15 | — |
| Shares | 103.8M | 103.8M | 75.9M | 101.8M | -1.9% | 103.8M | — | — | — |
| Debt | 12.0M | 30.6M | 28.3M | 55.7M | 67.0% | 58.1M | — | — | — |
| Equity | 303.7M | 200.5M | 527.0M | 538.7M | 21.1% | — | — | — | — |
| Op CF | -159.8M | -81.4M | -172.6M | -249.5M | — | -293.7M | — | — | — |
| Inv CF | 27.2M | 68.3M | -257.7M | 147.9M | — | — | — | — | — |
| Fin CF | 117.2M | 3.2M | 485.7M | 238.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NRIX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc.(you) | $2.4B | 30 | SELL |
| ATAI | AtaiBeckley Inc. | $2.7B | 31 | SELL |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.6B | 28 | SELL |
| NUVB | Nuvation Bio Inc. | $2.2B | 28 | SELL |
| PVLA | Palvella Therapeutics, Inc. | $2.0B | 30 | SELL |
| KOD | Kodiak Sciences Inc. | $2.6B | 27 | SELL |
| SION | Sionna Therapeutics, Inc. | $2.1B | 28 | SELL |
| AGIO | Agios Pharmaceuticals, Inc. | $2.2B | 34 | SELL |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.6B | 26 | SELL |
| IOVA | Iovance Biotherapeutics, Inc. | $2.2B | 35 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%